Pages that link to "Q44456352"
Jump to navigation
Jump to search
The following pages link to Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein (Q44456352):
Displaying 50 items.
- A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease (Q24306084) (← links)
- Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 (Q24802369) (← links)
- Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies (Q26738588) (← links)
- Cardioprotective functions of HDLs (Q27000421) (← links)
- High-Density Lipoproteins: Nature's Multifunctional Nanoparticles (Q28077290) (← links)
- Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection (Q28235893) (← links)
- GPR109A and vascular inflammation (Q28287747) (← links)
- Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. (Q30364133) (← links)
- Surrogate markers for atherosclerosis in overweight subjects with atherogenic dyslipidemia: the GEMS project (Q33326943) (← links)
- Tangier disease: epidemiology, pathophysiology, and management (Q33402921) (← links)
- High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation (Q33782094) (← links)
- The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? (Q33993233) (← links)
- Peripheral arterial tonometry for risk stratification in men with coronary artery disease (Q34038387) (← links)
- HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications (Q34181607) (← links)
- Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk (Q34253290) (← links)
- Apolipoprotein A-I Modulates Regulatory T Cells in Autoimmune LDLr−/−, ApoA-I−/− Mice (Q34285479) (← links)
- ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet (Q34657417) (← links)
- High-density lipoprotein: a novel target for antirestenosis therapy (Q34714464) (← links)
- Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis (Q34781496) (← links)
- eNOS activation by HDL is impaired in genetic CETP deficiency. (Q35168995) (← links)
- High-density lipoprotein cholesterol in diabetes: is higher always better? (Q35302241) (← links)
- Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease (Q35572369) (← links)
- HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease. (Q35754375) (← links)
- Gene-Activation Mechanisms in the Regression of Atherosclerosis, Elimination of Diabetes Type 2, and Prevention of Dementia (Q35767230) (← links)
- High-density lipoproteins: multifunctional vanguards of the cardiovascular system (Q35777408) (← links)
- Anti-inflammatory properties of HDL. (Q35919274) (← links)
- Molecular, cellular and functional imaging of atherothrombosis (Q35936423) (← links)
- Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. (Q35989396) (← links)
- Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease (Q36037988) (← links)
- HDL action on the vascular wall: is the answer NO? (Q36057080) (← links)
- Metabolic syndrome and endothelial dysfunction (Q36062224) (← links)
- Therapeutic approaches to raising plasma HDL-cholesterol levels (Q36304186) (← links)
- Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence (Q36314862) (← links)
- Cellular cholesterol homeostasis in vascular endothelial cells (Q36405130) (← links)
- Novel biological functions of high-density lipoprotein cholesterol (Q36406480) (← links)
- Therapeutic use of the high-density lipoprotein protein and peptides (Q36407298) (← links)
- New Insights into the High-Density Lipoprotein Dilemma (Q36450075) (← links)
- The rationale for using apoA-I as a clinical marker of cardiovascular risk (Q36455889) (← links)
- High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease (Q36539475) (← links)
- High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. (Q36611036) (← links)
- Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM. (Q36644225) (← links)
- Nanomedicines for Endothelial Disorders (Q36651592) (← links)
- ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. (Q36682924) (← links)
- HDL and endothelial protection. (Q36929420) (← links)
- Endothelial function, arterial stiffness and lipid lowering drugs (Q36936335) (← links)
- Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs (Q36985913) (← links)
- New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease (Q37000084) (← links)
- Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Endothelial Cells Accelerates Atherosclerosis in Mice (Q37033745) (← links)
- High-Density Lipoproteins, Endothelial Function, and Mendelian Randomization (Q37041783) (← links)
- Rapid regression of atherosclerosis: insights from the clinical and experimental literature (Q37068628) (← links)